Novan Announces First Patient Enrolled and Dosed in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
Novan announced the enrollment of the first patient in its pivotal Phase 3 clinical trial, B-SIMPLE4, for SB206, a topical gel targeting molluscum contagiosum. This common skin infection affects around six million Americans annually, primarily children. Currently, there are no FDA-approved treatments available. The trial aims to evaluate SB206's efficacy, with topline results expected by Q2 2021. The company emphasizes the unmet medical need for effective molluscum treatments. The trial's progress may be affected by COVID-19, with patient enrollment expected to conclude by Q1 2021.
- First patient enrolled in Phase 3 trial B-SIMPLE4 for SB206.
- SB206 addresses a significant unmet need as the only potential treatment for molluscum contagiosum.
- Topline results anticipated in Q2 2021, showing potential rapid development.
- Clinical trial progress may be impacted by the COVID-19 pandemic.
- No FDA-approved treatments currently available, indicating the high stakes for trial success.
- Topline results targeted for Q2 2021, less than a year away -
- SB206, if approved, has the potential to meet an important need for the treatment of molluscum, an area with no current FDA-approved treatment -
MORRISVILLE, N.C., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN), today announced the first patient has been enrolled and dosed in its B-SIMPLE4 pivotal Phase 3 clinical study of SB206, a topical antiviral gel, for the treatment of molluscum contagiosum (“molluscum”).
Molluscum contagiosum is a common, contagious skin infection caused by the molluscipoxvirus, affecting approximately six million people in the U.S. annually, with the greatest incidence in children aged one to 14 years.
“I believe that the design of the B-SIMPLE4 study positions us well to fully evaluate SB206 for the treatment of molluscum,” commented Elizabeth Messersmith, Ph.D, Senior Vice President and Chief Development Officer of Novan. “We are encouraged by the trends in efficacy as well as the safety profile SB206 has demonstrated to-date and look forward to continuing to advance development of this important program where there remains no FDA approved treatment.”
Completion of patient enrollment is targeted for the first quarter of 2021. Topline results from the B-SIMPLE4 trial are anticipated in the second quarter of 2021, subject to the targeted timing and trial execution plan which have been and may be further impacted by the COVID-19 pandemic.
There are currently no FDA-approved therapies for the treatment of molluscum. The Company believes that SB206 as a topical, at-home, caregiver-applied therapy with a rapid treatment benefit, if approved, would satisfy an important patient-care need for the treatment of molluscum.
For more information about the trial, please visit clinicaltrials.gov and reference identifier: NCT04535531.
About Molluscum
Molluscum contagiosum is a common, contagious skin infection caused by the molluscipoxvirus, affecting approximately six million people in the U.S. annually, with the greatest incidence in children aged one to 14 years. Infected children typically present with 10 to 30 painless, yet unsightly lesions, and, in severe cases, they can have around 100 lesions. Due to the largely pediatric nature of the disease, parents are the caregivers for these children, in most cases, and tend to seek treatment. There are no FDA-approved therapies for molluscum, and, upon seeking treatment, caregivers are faced with potentially painful in-office, dermatologist-administered physical procedures or cantharidin, or recommended off-label prescriptions and over-the-counter products. More than half of the patients diagnosed with molluscum are untreated and over
About Novan
Novan, Inc. is a clinical development-stage biotechnology company focused on leveraging nitric oxide’s naturally occurring anti-microbial and immunomodulatory mechanisms of action to treat a range of diseases with significant unmet needs. We believe that our ability to deploy nitric oxide in a solid form, on demand and in localized formulations allows us the potential to improve patient outcomes in a variety of dermatology, women’s health and gastrointestinal diseases.
Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, statements related to pharmaceutical development of nitric oxide-releasing product candidates and our intention to advance development of certain product candidates, including the timing, enrollment demand and progress of our Phase 3 program to evaluate SB206 for the treatment of molluscum and the timing of anticipated top-line results. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from our expectations, including, but not limited to, risks and uncertainties in the clinical development process, including, among others, length, expense, ability to enroll patients, reliance on third parties, potential for delays or other impacts, whether as a result of the COVID-19 pandemic or other factors, and that results of earlier research and preclinical or clinical trials may not be predictive of results, conclusions or interpretations of later research activities or additional trials; risks related to the regulatory approval process, which is lengthy, time-consuming and inherently unpredictable, including the risk that our product candidates may not be approved or that additional studies may be required for approval or other delays may occur and that we may not obtain funding sufficient to complete the regulatory or development process; our ability to obtain additional funding or enter into strategic or other business relationships necessary or useful for the further development of our product candidates; the risk that disruptions at the FDA or other agencies could cause such agencies to cancel or postpone meetings or otherwise impact the ability of such agencies to provide regulatory guidance or feedback or timely review and process our regulatory submissions, all of which could have a material adverse effect on our business; risks related to the manufacture of clinical trial materials; any operational or other disruptions as a result of the COVID-19 pandemic, including any delays or disruptions to the enrollment in and conduct of the B-SIMPLE4 Phase 3 trial; and other risks and uncertainties described in our annual report filed with the SEC on Form 10-K for the twelve months ended December 31, 2019, as amended, and in our subsequent filings with the SEC. These forward-looking statements speak only as of the date of this press release, and Novan disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.
INVESTOR AND MEDIA CONTACT:
Jenene Thomas
JTC Team, LLC
833-475-8247
NOVN@jtcir.com
FAQ
What is the purpose of the B-SIMPLE4 trial for NOVN?
When are topline results expected from NOVN's B-SIMPLE4 trial?
How many people are affected by molluscum contagiosum in the U.S.?
What is SB206 and its potential significance for NOVN?
What challenges could affect NOVN's clinical trial for SB206?
